» Articles » PMID: 35249211

Italian Guidelines on Management of Persons with Multimorbidity and Polypharmacy

Abstract

Multimorbidity and polypharmacy are emerging health priorities and the care of persons with these conditions is complex and challenging. The aim of the present guidelines is to develop recommendations for the clinical management of persons with multimorbidity and/or polypharmacy and to provide evidence-based guidance to improve their quality of care. The recommendations have been produced in keeping with the Grading of Recommendations Assessment, Development and Evaluation (GRADE). Overall, 14 recommendations were issued, focusing on 4 thematic areas: (1.) General Principles; (2.) target population for an individualized approach to care; (3.) individualized care of patients with multimorbidity and/or polypharmacy; (4.) models of care. These recommendations support the provision of individualized care to persons with multimorbidity and/or polypharmacy as well as the prioritization of care through the identification of persons at increased risk of negative health outcomes. Given the limited available evidence, recommendations could not be issued for all the questions defined and, therefore, some aspects related to the complex care of patients with multimorbidity and/or polypharmacy could not be covered in these guidelines. This points to the need for more research in this field and evidence to improve the care of this population.

Citing Articles

Operational Definitions of Polypharmacy and Their Association with All-Cause Hospitalization Risk: A Conceptual Framework Using Administrative Databases.

Scotti S, Scotti L, Galimberti F, Xie S, Casula M, Olmastroni E Pharmacy (Basel). 2025; 13(1).

PMID: 39998013 PMC: 11859879. DOI: 10.3390/pharmacy13010015.


The co-occurrence of multimorbidity and polypharmacy among middle-aged and older adults in Canada: A cross-sectional study using the Canadian Longitudinal Study on Aging (CLSA) and the Canadian Primary Care Sentinel Surveillance Network (CPCSSN).

Nicholson K, Salerno J, Borhan S, Cossette B, Guenter D, Vanstone M PLoS One. 2025; 20(1):e0312873.

PMID: 39813217 PMC: 11734935. DOI: 10.1371/journal.pone.0312873.


Medication review and deprescribing in different healthcare settings: a position statement from an Italian scientific consortium.

Carollo M, Boccardi V, Crisafulli S, Conti V, Gnerre P, Miozzo S Aging Clin Exp Res. 2024; 36(1):63.

PMID: 38459218 PMC: 10923734. DOI: 10.1007/s40520-023-02679-2.


Applying precision medicine principles to the management of multimorbidity: the utility of comorbidity networks, graph machine learning, and knowledge graphs.

Woodman R, Koczwara B, Mangoni A Front Med (Lausanne). 2024; 10:1302844.

PMID: 38404463 PMC: 10885565. DOI: 10.3389/fmed.2023.1302844.


Developing quality measures for non-pharmacological prevention and rehabilitation in primary health care for chronic conditions: a consensus study.

Svendsen M, Andersen T, Soendergaard H Int J Qual Health Care. 2023; 35(4).

PMID: 38079511 PMC: 10712901. DOI: 10.1093/intqhc/mzad097.


References
1.
Marengoni A, Onder G . Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity. BMJ. 2015; 350:h1059. DOI: 10.1136/bmj.h1059. View

2.
Vetrano D, Palmer K, Marengoni A, Marzetti E, Lattanzio F, Roller-Wirnsberger R . Frailty and Multimorbidity: A Systematic Review and Meta-analysis. J Gerontol A Biol Sci Med Sci. 2018; 74(5):659-666. DOI: 10.1093/gerona/gly110. View

3.
Khezrian M, McNeil C, Murray A, Myint P . An overview of prevalence, determinants and health outcomes of polypharmacy. Ther Adv Drug Saf. 2020; 11:2042098620933741. PMC: 7294476. DOI: 10.1177/2042098620933741. View

4.
Zazzara M, Palmer K, Vetrano D, Carfi A, Onder G . Adverse drug reactions in older adults: a narrative review of the literature. Eur Geriatr Med. 2021; 12(3):463-473. PMC: 8149349. DOI: 10.1007/s41999-021-00481-9. View

5.
Wastesson J, Morin L, Tan E, Johnell K . An update on the clinical consequences of polypharmacy in older adults: a narrative review. Expert Opin Drug Saf. 2018; 17(12):1185-1196. DOI: 10.1080/14740338.2018.1546841. View